الفهرس 
Immunoglobulin EOnly 14 pages are availabe for public view
 |  | from | 177 |  |  |
| | | from | 177 | | |
Abstract
Colorectal carcinoma (CRC) is the third most common non-skin cancer in the United States after lung cancer in both men and women, with an annual incidence of 42.9 per 100,000 people. It accounts for 8% of cancer-related deaths in the US alone (Bibbins-Domingo et al., 2016).
Colorectal cancer is the 7th commonest cancer in Egypt, representing 3.47% of male cancers and 3% of female cancers (Metwally et al., 2018).
Links between IgE or IgE-mediated diseases and malignancy have been reported with early studies finding decreased cancer risk associated with the presence of allergy and decreased prevalence of atopy in cancer patients (McCraw et al., 2021). In cancer patients themselves, there is evidence to suggest that higher IgE levels may correlate to a prolonged survival compared to those with low or even average levels (Bankova & Barrett, 2019).
In the current study, that the Best cut off value of total IgE to differentiae between CRC cases and healthy controls was > 42.50 IU\mLwith sensitivity=57.1% and Specificity = 53.8%.
In the current study, there was a statistical significance regarding the level of total IgE between CRC cases and controls p value =0.05. Twelve ( 20%) CRC patients had total IgE level between 5-10 (IU\ml), 37 patients had total IgE level 10-100 (IU\mL), 11 patients with total IgE level>100 (IU\mL). 20 CRC patients were stage II, 19 patients were stage III, 21 patients were stage IV. 54 patients were diagnosed with adenocarcinoma, two patients with Mucinous adenocarcinoma, two patients had Tubulovillous adenocarcinoma, one patient had Villous adenocarcinoma, and one patient had squamous cell carcinoma (SCC). 18 patients had rectal carcinoma, 40 patients had only the Colonic carcinoma, and only two patients had both colo- rectal carcinoma.
In the current study, that the Best cut off value of total IgE to differentiae between CRC cases and healthy controls was >42.50 IU\mLwith sensitivity=57.1% and Specificity = 53.8%.
In the current study, 20 CRC patients were stage II, 19 patients were stage III, 21 patients were stage IV.